AbbVie and Genmab A/S announced that adult patients with relapsed/refractory follicular lymphoma previously treated with two or more prior therapies experienced strong and durable responses with high overall response and complete response rates when treated with epcoritamab, an investigational, subcutaneously administered T-cell engaging bispecific antibody.
